Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Regulation of resistance to CDK4/6 inhibitor in breast cancer

Award Number: R01CA275904
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 03/22/2023
PERIOD OF PERFORMANCE END DATE: 02/29/2028

Group Awards By:

View Award Description

Regulation of resistance to CDK4/6 inhibitor in breast cancer - Project Summary Cyclin-dependent kinase CDK4/6 inhibitor (CDK4/6i) in combination with aromatase inhibitors is the first-line treatment for ER+ advanced or metastatic breast cancer. Despite CDK4/6 inhibitors significantly improve overall survival of such patients, not all patients respond to these drugs and most patients whose tumors initially respond to CDK4/6i eventually develop acquired resistance. Although many efforts have been invested into the studying mechanism of resistance, CDK4/6i resistance remains a big challenge for HR+ breast cancer. Thus, it is urgent to develop new approaches to overcome resistance in CDK4/6i resistant breast cancer (CRBC). O-linked-N-acetylglucosaminylation (O-GlcNAcylation) is one type of glycosylation that occurs when a monosaccharide, O-GlcNAc, is added onto serine or threonine residues of proteins by O-GlcNAc transferase (OGT). O-GlcNAcylation is involved in a range of cellular activities and aberrant O-GlcNAcylation has been implicated in a host of diseases including cancer. However, the role of O-GlcNAcylation in cancer drug resistance remains largely unknown. Through an innovative quantitative high throughput combination screen (qHTCS) and follow-up extensive preliminary studies using cellular and molecular approaches, we identified a novel OGT-mediated mechanism regulating the resistance to CDK4/6i in ER+ breast cancer. The major objective of this proposal is to determine the role of OGT-mediated pathway in the regulation of CDK4/6i resistance in CRBC cells. Specifically, we will (1) investigate the molecular mechanism of how OGT-mediated pathway regulates CDK4/6i resistance in CRBC cells, (2) evaluate the effects of newly identified drug combinational treatments on palbociclib resistance using resistant PDX and syngeneic models, (3) conduct clinical study to further evaluate the correlation between OGT-mediated pathway and CDK4/6i resistance in tumors from patients. The completion of proposed studies will not only elucidate a novel mechanism regulating CDK4/6i resistance in ER+ breast cancer, but also provide an innovative therapeutic strategy to treat CRBC patients.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $633,959 )
2026	2026	GEORGE WASHINGTON UNIVERSITY (THE)	1918 F ST NW	WASHINGTON	DC	20052	DISTRICT OF COLUMBIA	USA	Cancer Treatment Research	000	4	3/6/2026	NON-COMPETING CONTINUATION	$633,959
														Subtotal = $633,959

Issue Date FY: 2025 ( Subtotal = $633,959 )
2025	2025	GEORGE WASHINGTON UNIVERSITY (THE)	1918 F ST NW	WASHINGTON	DC	20052	DISTRICT OF COLUMBIA	USA	Cancer Treatment Research	000	3	2/12/2025	NON-COMPETING CONTINUATION	$570,564
2025	2025	GEORGE WASHINGTON UNIVERSITY (THE)	1918 F ST NW	WASHINGTON	DC	20052	DISTRICT OF COLUMBIA	USA	Cancer Treatment Research	001	3	5/22/2025	NON-COMPETING CONTINUATION	$63,395
														Subtotal = $633,959

Issue Date FY: 2024 ( Subtotal = $602,262 )
2024	2024	GEORGE WASHINGTON UNIVERSITY (THE)	1918 F ST NW	WASHINGTON	DC	20052	DISTRICT OF COLUMBIA	USA	Cancer Treatment Research	000	2	2/23/2024	NON-COMPETING CONTINUATION	$570,564
2024	2024	GEORGE WASHINGTON UNIVERSITY (THE)	1918 F ST NW	WASHINGTON	DC	20052	DISTRICT OF COLUMBIA	USA	Cancer Treatment Research	001	2	4/16/2024	NON-COMPETING CONTINUATION	$31,698
														Subtotal = $602,262

Issue Date FY: 2023 ( Subtotal = $650,485 )
2023	2023	GEORGE WASHINGTON UNIVERSITY, THE	1918 F ST NW	WASHINGTON	DC	20052	DISTRICT OF COLUMBIA	USA	Cancer Treatment Research	000	1	3/22/2023	NEW	$650,485
														Subtotal = $650,485

Grand Total All Awards = $2,520,665

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Regulation of resistance to CDK4/6 inhibitor in breast cancer

Award Number: R01CA275904

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 03/22/2023

PERIOD OF PERFORMANCE END DATE: 02/29/2028

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer